JP7702427B2 - 炎症性腸疾患を治療するための５－クロロ－４－ヒドロキシ－１－メチル－２－オキソ－ｎ－フェニル－キノリン－３－カルボキサミドカリウム塩 - Google Patents

炎症性腸疾患を治療するための５－クロロ－４－ヒドロキシ－１－メチル－２－オキソ－ｎ－フェニル－キノリン－３－カルボキサミドカリウム塩 Download PDF

Info

Publication number
JP7702427B2
JP7702427B2 JP2022566660A JP2022566660A JP7702427B2 JP 7702427 B2 JP7702427 B2 JP 7702427B2 JP 2022566660 A JP2022566660 A JP 2022566660A JP 2022566660 A JP2022566660 A JP 2022566660A JP 7702427 B2 JP7702427 B2 JP 7702427B2
Authority
JP
Japan
Prior art keywords
compound
oxo
quinoline
hydroxy
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022566660A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023524518A (ja
JP2023524518A5 (https=
Inventor
ハンス ヨハンソン，マーティン
マルコム クロウ，ディヴィッド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aqilion AB
Original Assignee
Aqilion AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aqilion AB filed Critical Aqilion AB
Publication of JP2023524518A publication Critical patent/JP2023524518A/ja
Publication of JP2023524518A5 publication Critical patent/JP2023524518A5/ja
Application granted granted Critical
Publication of JP7702427B2 publication Critical patent/JP7702427B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2022566660A 2020-04-30 2021-04-30 炎症性腸疾患を治療するための５－クロロ－４－ヒドロキシ－１－メチル－２－オキソ－ｎ－フェニル－キノリン－３－カルボキサミドカリウム塩 Active JP7702427B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2006390.5 2020-04-30
GBGB2006390.5A GB202006390D0 (en) 2020-04-30 2020-04-30 Novel treatments
PCT/EP2021/061464 WO2021219881A1 (en) 2020-04-30 2021-04-30 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-quinoline-3-carboxamide potassium salt for treating inflammatory bowel diseases

Publications (3)

Publication Number Publication Date
JP2023524518A JP2023524518A (ja) 2023-06-12
JP2023524518A5 JP2023524518A5 (https=) 2024-05-10
JP7702427B2 true JP7702427B2 (ja) 2025-07-03

Family

ID=71080611

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022566660A Active JP7702427B2 (ja) 2020-04-30 2021-04-30 炎症性腸疾患を治療するための５－クロロ－４－ヒドロキシ－１－メチル－２－オキソ－ｎ－フェニル－キノリン－３－カルボキサミドカリウム塩
JP2022566661A Pending JP2023524519A (ja) 2020-04-30 2021-04-30 炎症性腸疾患の治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022566661A Pending JP2023524519A (ja) 2020-04-30 2021-04-30 炎症性腸疾患の治療

Country Status (9)

Country Link
US (2) US20230167064A1 (https=)
EP (2) EP4142725A1 (https=)
JP (2) JP7702427B2 (https=)
KR (2) KR20230018386A (https=)
CN (2) CN115768429B (https=)
AU (2) AU2021262514A1 (https=)
CA (2) CA3177000A1 (https=)
GB (2) GB202006390D0 (https=)
WO (2) WO2021219881A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202006390D0 (en) * 2020-04-30 2020-06-17 Aqilion Ab Novel treatments
CN115836056A (zh) * 2020-05-21 2023-03-21 Stemsynergy疗法有限责任公司 Notch抑制剂及其用途
CN115120727B (zh) * 2022-06-16 2024-02-23 甘肃农业大学 S100a9抑制剂在制备防治c型产气荚膜梭菌感染性腹泻药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013543504A (ja) 2010-10-14 2013-12-05 イムナール アクティエボラーグ Ａｈｒ活性化因子としての１，２‐ジヒドロ‐４‐ヒドロキシ‐２‐オキソ‐キノリン‐３‐カルボキシアニリド

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52670B1 (en) * 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
SE9400809D0 (sv) * 1994-03-10 1994-03-10 Pharmacia Ab New use of quinoline-3-carboxamide compounds
ES2393814T3 (es) * 2007-04-04 2012-12-28 Sigmoid Pharma Limited Una composición farmacéutica oral
PL2458992T3 (pl) * 2009-07-30 2016-07-29 Teva Pharma Leczenie choroby Leśniowskiego-Crohna z użyciem lakwinimodu
WO2012006538A1 (en) * 2010-07-09 2012-01-12 Teva Pharmaceutical Industries Ltd. Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
EP2590653A4 (en) * 2010-07-09 2014-01-01 Teva Pharma 5-CHLORO-4-HYDROXY-1-METHYL-2-OXO-N-PHENYL-1,2-DIHYDROCHINOLINE-3-CARBOXAMIDE, SALT THEREOF AND APPLICATIONS THEREOF
US9200046B2 (en) * 2011-06-29 2015-12-01 Cornell University Reporter system for high throughput screening of compounds and uses thereof
GB202006390D0 (en) * 2020-04-30 2020-06-17 Aqilion Ab Novel treatments

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013543504A (ja) 2010-10-14 2013-12-05 イムナール アクティエボラーグ Ａｈｒ活性化因子としての１，２‐ジヒドロ‐４‐ヒドロキシ‐２‐オキソ‐キノリン‐３‐カルボキシアニリド

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BASTIN, R. J. et al.，Salt Selection and Optimisation Procedures for Pharmaceutical New Chemical Entities，Organic Process research & Development，2000年，Vol.4，pp.427-435，DOI:10.1021/op000018u
Milad Reda Qelliny et al.，Colon Drug Delivery Systems for the Treatment of Inflammatory Bowel Disease，J. Adv. Biomed. & Pharm. Sci.，2019年，2，164-184
Selma Mahiout et al.，In vitro toxicity and in silico docking analysis of two novel selective AH-receptor modulators，Toxicology in Vitro，2018年，52，178-188，DOI: 10.1016/j.tiv.2018.06.010
Timothy Scott Wiedmann, and Amir Naqwi，Pharmaceutical salts: Theory, use in solid dosage forms and in situ preparation in an aerosol，Asian journal of pharmaceutical sciences，11，2016年，722-734，DOI: 10.1016/j.ajps.2016.07.002
小嶌隆史，医薬品開発における結晶性選択の効率化を目指して，薬剤学，2008年09月01日，Vol.68, No.5，pp.344-349
芦澤一英，医薬品の多形現象と晶析の化学，2002年，pp.273,278,305-317

Also Published As

Publication number Publication date
WO2021219881A1 (en) 2021-11-04
CA3176994A1 (en) 2021-11-04
GB202006390D0 (en) 2020-06-17
CN115768429A (zh) 2023-03-07
AU2021262514A1 (en) 2023-01-05
JP2023524518A (ja) 2023-06-12
GB2605894A (en) 2022-10-19
CN115916200A (zh) 2023-04-04
CA3177000A1 (en) 2021-11-04
WO2021219879A1 (en) 2021-11-04
EP4142724A1 (en) 2023-03-08
US20230167064A1 (en) 2023-06-01
GB2605894B (en) 2023-06-14
KR20230024892A (ko) 2023-02-21
CN115768429B (zh) 2024-02-09
GB202207709D0 (en) 2022-07-06
KR20230018386A (ko) 2023-02-07
EP4142725A1 (en) 2023-03-08
AU2021266154A1 (en) 2023-01-05
US20230202982A1 (en) 2023-06-29
JP2023524519A (ja) 2023-06-12

Similar Documents

Publication Publication Date Title
JP7702427B2 (ja) 炎症性腸疾患を治療するための５－クロロ－４－ヒドロキシ－１－メチル－２－オキソ－ｎ－フェニル－キノリン－３－カルボキサミドカリウム塩
EP3269719B1 (en) Crystal form of jak inhibitor and preparation method thereof
JP2006504734A (ja) 塩基性賦形剤を含有する安定化医薬組成物
WO2012020016A1 (en) Crystalline form of pyrimidio[6,1-a]isoquinolin-4-one compound
US20030191347A1 (en) Venlafaxine base
EP4233871A2 (en) Inhibiting the transient receptor potential a1 ion channel
EP3389632A1 (en) Amorphous onapristone compositions and methods of making the same
US20110034498A1 (en) Dosing regimens for the treatment of cancer
US12048689B2 (en) Pharmaceutical composition for preventing or treating inflammatory bowel disease acting as a functional antagonist for S1PR1 and S1PR4
EP3880683B1 (en) Monohydrate potassium salt of a thienopyridone derivative and its preparation process
CN104628708A (zh) 一种阿伐那非的晶型及其制备方法、用途和药物组合物
US20230303542A1 (en) Solid forms of a parp14 inhibitor
JP5888612B2 (ja) 縮合ピリジン化合物塩の結晶
CN101993417A (zh) 磷酸二甲啡烷的稳定新晶型
CN117736193A (zh) 一种氘代稠环化合物及其制备方法与用途
TWI898321B (zh) 用於治療或預防高尿酸血症或痛風的化合物的固體晶型
WO2020225783A1 (ko) Pi3k 저해제의 결정다형 및 이의 제조방법
HK40056406B (en) Monohydrate potassium salt of a thienopyridone derivative and its preparation process
WO2020187674A1 (en) Crystalline (s)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl][3-hydroxy-3-(piperidin-2-yl)azetidin-1-yl]methanone hemisuccinate

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240426

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240426

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250415

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250528

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250623

R150 Certificate of patent or registration of utility model

Ref document number: 7702427

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150